Form 4: Arcutis Biotherapeutics CFO Sells Shares to Cover Tax Obligations

David Joseph Topper, CFO of Arcutis Biotherapeutics, sold 9,600 shares of common stock on April 2, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, Inc., reported a transaction involving the sale of company stock.
• On April 2, 2025, Topper sold 9,600 shares of common stock at a weighted average price of $15.8019 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on April 10, 2024.
• Following the transaction, Topper directly owns 182,774 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 6

Explanation: The document reports a routine transaction (sale of shares to cover taxes). It's neutral, but the fact that the CFO is selling shares, even for tax purposes, might be perceived slightly negatively by some investors.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally viewed as routine.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by shareholders, although this is a routine transaction to cover tax obligations.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, David Joseph Topper, CFO, stock sale, Form 4, insider trading, restricted stock units, tax withholding